EP. 1: How Ponatinib Factors into the Treatment of a Type of Leukemia
Kendra Sweet, MD, discussed results of the the phase 2 OPTIC trial, which investigated ponatinib in a group of patients with resistant, chronic phase chronic myeloid leukemia.
EP. 2: The Implications of CML Data From ASH, And Important Takeaways for Providers
Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.
EP. 3: Highlighting Ongoing Clinical Trials in CML From ASH
Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
EP. 4: Phase 3 ASCEMBL Study Demonstrates Superiority of Asciminib in CML-CP
Talha Badar, MBBS, MD, discussed the results of the phase 3 ASCEMBL trial, demonstrating the superiority of asciminib versus bosutinib in patients with chronic myeloid leukemia in chronic phase.
EP. 5: Superiority of Asciminib in CML-CP Is a ‘Win-Win’ for Patients
Talha Badar, MBBS, MD, discussed the unmet needs in the treatment of chronic myeloid leukemia in chronic phase.
EP. 6: Asciminib Offers Additional Tool to Treat CML-CP
Talha Badar, MBBS, MD, discussed how results from the phase 3 ASCEMBL study of asciminib will impact clinical practice in treating chronic myeloid leukemia in chronic phase.
EP. 7: Ongoing Studies in CML-CP Offer Hope to Future Treatments
Talha Badar, MBBS, MD, discussed ongoing trials in the treatment of chronic myeloid leukemia in chronic phase, as well as his hope for future therapies in the space.
EP. 8: Recap: Moffitt and Mayo Face-Off in CML Treatment Updates From ASH
A panel of experts from Moffitt and Mayo discuss newly published data from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.
2 Clarke Drive Cranbury, NJ 08512